InsidersTradesSigma
iTeos Therapeutics, Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the iTeos Therapeutics, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, iTeos Therapeutics, Inc. has published 183 insider filings. The latest transaction was filed on 16 May 2025 (Acquisition). Among the most active insiders: MPM BioVentures 2014, L.P.. Every trade is accessible without an account.
183
Insider Decl.
0
Thresholds
€12m
6 ops.
Buy Volume
€147m
121 ops.
Sell Volume
22Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 16 May 2025
Declarations183 total
1,658,978 shares@ US$7.4055100.0% of flowCommon StockSEC:0000935836-25-000384:0
Ideal exit: 8 Feb 2026 (T+270)
630,191 shares@ US$8.0620.0% of flowCommon StockSEC:0001415889-25-013248:0
1,031,931 shares@ US$8.0619.7% of flowCommon StockSEC:0001415889-25-013252:0
630,191 shares@ US$8.0620.0% of flowCommon StockSEC:0001415889-25-013251:0
22,346 shares@ US$4.30100.0% of flowCommon StockSEC:0000950170-25-071755:0
15,300 shares0Common StockSEC:0000950170-25-037513:0
77,000 shares0Common StockSEC:0000950170-25-037515:0
24,000 shares0Common StockSEC:0000950170-25-037520:0
24,000 shares0Common StockSEC:0000950170-25-037512:0
47,000 shares0Common StockSEC:0000950170-24-134239:0
5,000 shares@ US$7.7274.3% of flowCommon StockSEC:0000950170-24-128956:0
Ideal exit: 16 Aug 2025 (T+270)
900,000 sharesCommon StockSEC:0001415889-24-013171:0
1,142,857 shares@ US$17.5025.2% of flowCommon StockSEC:0000895345-24-000172:0
30,000 shares0Common StockSEC:0000950170-23-068900:0
31,000 shares0Common StockSEC:0000950170-23-068903:0
44,000 shares0Common StockSEC:0000950170-23-068902:0
41,000 shares0Common StockSEC:0000950170-23-068901:0
5,000 shares@ US$8.374.6% of flowCommon StockSEC:0001209191-23-052709:0
Ideal exit: 8 Jul 2024 (T+270)
34,846 shares@ US$14.190.6% of flowCommon StockSEC:0000895345-23-000524:0
40,226 shares@ US$2.9529.1% of flowCommon StockSEC:0001209191-23-021566:0
5,968 shares@ US$4.2313.3% of flowCommon StockSEC:0001209191-22-036137:0
25,000 shares@ US$22.908910.7% of flowCommon StockSEC:0000899243-22-017712:0
150,000 shares@ US$27.402177.2% of flowCommon StockSEC:0000899243-22-016203:0
11,500 shares@ US$4.231.0% of flowCommon StockSEC:0001209191-22-024859:0
21,300 shares@ US$31.87512.2% of flowCommon StockSEC:0000899243-22-012152:0
Ideal exit: 17 Dec 2022 (T+270)
25 of 183 declarations
About iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. is a U.S.-listed biopharmaceutical company trading on NASDAQ in the United States, focused on immuno-oncology. The company is headquartered in Watertown, Massachusetts, with a research center in Gosselies, Belgium. Its roots go back to a Belgian biotechnology platform founded in 2011, and the current Delaware-incorporated parent, iTeos Therapeutics, Inc., was created in 2019 as the U.S. successor structure. iTeos operates as a clinical-stage oncology company, with a portfolio centered on monoclonal antibodies and small molecules designed to address validated immune pathways, especially in solid tumors. The company’s lead asset is belrestotug, an anti-TIGIT antibody intended to counter tumor-induced immunosuppression and enhance anti-tumor immune activity. iTeos developed this program in collaboration with GSK under a global collaboration and license agreement that gives GSK commercialization rights outside the United States, while iTeos and GSK share development responsibility and U.S. commercial rights. This partnership has been a key strategic asset for iTeos, providing scientific validation, cost-sharing, and significant milestone potential. The broader pipeline has also included adenosine-pathway programs such as inupadenant (EOS-850), although the company stated in 2024 that the interim data did not justify further investment at that stage. From a competitive standpoint, iTeos operates in one of the most crowded and scientifically demanding areas of oncology drug development. Success depends on clinical differentiation, biomarker strategy, partner quality, and capital efficiency. The company’s main strengths are its translational tumor immunology expertise, its cross-border U.S.-Belgium operating model, and its ability to collaborate with a large pharmaceutical partner. At the same time, the business profile remains typical of a late-stage biotech: concentrated pipeline risk, high R&D intensity, and limited revenue visibility absent product commercialization. The GSK alliance has been central in positioning iTeos as a credible immuno-oncology developer rather than a purely preclinical story. Geographically, iTeos maintains a transatlantic footprint, with operational capabilities in both the United States and Belgium. A major recent development is the definitive agreement announced in July 2025 for Concentra Biosciences to acquire iTeos for $10.047 in cash per share plus a contingent value right, following a strategic review and board approval. For investors, this means iTeos should be viewed as a biotech asset with notable strategic optionality, but also as a company whose equity story is now closely tied to a transaction outcome rather than only to standalone pipeline execution.
